The website may be down at times on Saturday, November 30, and Sunday, December 1, for maintenance.
April 28, 2020 12:18 pm News Staff – On April 21, the U.S. Preventive Services Task Force issued a draft recommendation statement and draft evidence review on screening for high blood pressure in children and adolescents.
Based on its review of the evidence, the USPSTF concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for HBP in these populations. This is an "I" recommendation.
"High blood pressure is a growing problem for children and teens in the United States," said task force member Michael Silverstein, M.D., M.P.H., in a news release. "Unfortunately, there is not enough evidence to determine if screening for high blood pressure in youth helps detect and prevent other health problems, such as heart disease."
The recommendation applies to children and adolescents who are not known to have hypertension. Clinicians are advised to use their own judgment about whether to screen young patients who show no signs or symptoms of the condition and to consider factors such as potential preventable burdens, potential harms and current practices.
The task force issued a final recommendation on the same topic in 2013 and concluded at that time that the available evidence was insufficient to assess the balance of benefits and harms of screening for primary hypertension in asymptomatic children and adolescents to prevent subsequent cardiovascular disease in childhood or adulthood. The AAFP supported the recommendation at that time.
To update its previous recommendation, the USPSTF commissioned a systematic literature review on the benefits of screening, test accuracy, the effectiveness and harms of treatment, and the association between hypertension and markers of CVD in childhood and adulthood. The review included 42 studies published between June 1, 2012, and Sept. 3, 2019.
STORY HIGHLIGHTS
The task force found no direct evidence that compared screening with no screening in asymptomatic children and adolescents. Although results from epidemiological studies indicated an association between hypertension in childhood and adolescence and hypertension in adulthood, and results from longitudinal cohort studies showed an association between hypertension in adolescents and young adults and end-stage renal disease and death from cerebrovascular events in adulthood, the proportion of spontaneous resolution of hypertension in children and long-term benefits and harms of treatment of hypertension in children and adolescents were unclear. In addition, the evidence regarding whether the diagnostic accuracy of blood pressure measurements was adequate for screening asymptomatic children and adolescents in primary care was inconclusive.
The USPSTF recommendation statement pointed to a 2017 American Academy of Pediatrics clinical practice guideline on screening for and managing HBP in children and adolescents that recommended, among other things, screening all patients for HBP annually and screening high-risk patients at each visit beginning at age 3 years. The Academy gave that guideline its affirmation of value designation in February 2018.
In addition, the task force's draft statement noted that whereas the AAFP's stance is that the evidence is insufficient to recommend for or against routine screening, both the American Heart Association and the National Heart, Lung and Blood Institute recommend routine screening beginning at age 3.
The task force noted several evidence gaps that it said must be addressed to better understand the potential net benefits of HBP screening in children and adolescents. Specifically, additional research is needed to
"We know that children and teens who have high blood pressure are more likely to have it as adults, said task force member Martha Kubik, Ph.D., R.N., in the news release. "However, more research is needed on whether early identification and lowering of blood pressure in youth leads to improved cardiovascular health in youth or adults."
The USPSTF is accepting comments on the draft recommendation statement and draft evidence review until 8 p.m. ET on May 18, 2020. All comments received will be considered as the task force prepares its final recommendation.
The AAFP will review the USPSTF's draft recommendation statement and supporting evidence and will provide comments. The Academy will release its own recommendations on the topic after the task force finalizes its guidance.